U.S. FDA To Review Mylan's Application For Generic Copaxone; India Partner Natco Expects To Cross More Hurdles
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Oncology drug maker Natco and its partner Mylan moved a step closer to a possible launch of a generic version of Teva's blockbuster multiple sclerosis drug Copaxone (glatiramer) after U.S. FDA accepted Natco's application for review
You may also be interested in...
India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?
MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now
India's Natco Eyes Generic For Celgene's Mega Brand Revlimid; Will REMS Scuttle The Move?
MUMBAI - Although U.S.-headquartered Celgene succeeded last year in preventing India's Dr. Reddy's Labs from conducting bioequivalence studies on its fast-growing multiple myeloma drug Revlimid (lenalidomide) - due to risk management and restricted distribution issues - it may have a much harder fight on its hands now
Indian Government Denies Patent Application For Copaxone; Natco Pharma Says Obstacles Removed For Supply Of Generic Version Worldwide
MUMBAI - In a decision that could trigger a bigger battle, the Indian Patent Office has denied a patent application filed by an Israeli company for Copaxone(glatiramer), an innovative drug used in the treatment of multiple sclerosis